Pharming Group NV（PHAR）股票分析PHARPharming Group NV

Pharming Group NV is a biopharmaceutical company based in the Netherlands. The Company is engaged in the development, production and commercialization of human therapeutic proteins to be used in the therapies. The Company's product portfolio is aimed at treatments for genetic disorders, blood-related disorders, infectious and inflammatory diseases, tissue and bone damage and surgical/traumatic bleeding. Its core product, RUCONEST (conestat alfa) is a recombinant human C1 esterase inhibitor approved for the treatment of acute Hereditary Angioedema (HAE) attacks in patients in Europe, the Unites States, Israel and South Korea. The product is available on a named-patient basis in other territories where it has not yet obtained marketing authorization. It operates in the Healthcare sector.

Pharming Group NV is not a good buy right now due to its current price of $9.36, which is significantly below the analyst price target range of $37 to $40. Additionally, the stock has a high forward P/E ratio of 212.77, indicating overvaluation concerns. The RSI is at 30.07, suggesting the stock is oversold, but this could indicate further downside risk rather than an immediate buying opportunity.